Self-pay still important in China's health system
This article was originally published in Scrip
An analysis of patient records from one major hospital in a provincial capital city in China indicates just how important the self-pay market in the country still is, despite the steady national expansion of rural and other medical insurance schemes.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.